Supplementary Figure 1. Effect of idelalisib on the viability of IL-1β-treated orbital fibroblasts. Orbital fibroblasts from individuals with (black columns) and without (white columns) GO were seeded in 24-well culture plates and treated with various concentrations (0–10 μM) of idelalisib for 48 h (A) and 72 h (B) with 10 ng/ml IL-1β. After treatment, MTS assays were used to evaluate viability. Assays were performed in duplicate using cells from three different donors. Results are expressed as percentages of untreated control values and as means ± SD.
Supplementary Figure 2. Effect of idelalisib on the IL-1β-induced phosphorylation of NFκB in orbital fibroblasts. Confluent orbital fibroblasts derived from individuals with (black columns) and without (white columns) GO were either untreated or pretreated with various concentrations of idelalisib for 24 h prior to treatment with 10 ng/ml IL-1β for 1 h. The total and phosphorylated NFκB (p-NFκB) levels were determined in total protein extracts by western blotting. Values are presented as the mean ratio of phosphorylation and total levels of NFκB ± SD of three experiments. (*P < 0.05 and **P < 0.01 versus IL-1β-treated cells without pretreatment)